scispace - formally typeset
A

Aaron Pollett

Researcher at University of Toronto

Publications -  102
Citations -  9443

Aaron Pollett is an academic researcher from University of Toronto. The author has contributed to research in topics: Cancer & Lynch syndrome. The author has an hindex of 37, co-authored 95 publications receiving 8620 citations. Previous affiliations of Aaron Pollett include Lunenfeld-Tanenbaum Research Institute & Mount Sinai Hospital, Toronto.

Papers
More filters
Journal ArticleDOI

A human colon cancer cell capable of initiating tumour growth in immunodeficient mice

TL;DR: The identification of colon cancer stem cells that are distinct from the bulk tumour cells provides strong support for the hierarchical organization of human colon cancer, and their existence suggests that for therapeutic strategies to be effective, they must target the cancer stem Cells.
Journal ArticleDOI

Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer

TL;DR: Combining DNA copy number alteration (CNA) profiling, sequencing, and lentiviral lineage tracking, this work followed the repopulation dynamics of 150 single lentivirus-marked lineages from 10 human colorectal cancers through serial xenograft passages in mice, showing that clones remained stable upon serial transplantation and Chemotherapy promoted the dominance of previously minor or dormant lineages.
Journal ArticleDOI

Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients

TL;DR: Compared with the M probe, the FibroScan XL probe reduces TE failure and facilitates reliable LSM in obese patients, and lower liver stiffness cutoffs will be necessary when the XL probe is used to noninvasively assess liver fibrosis.
Journal ArticleDOI

Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers.

TL;DR: A new mechanism of cancer progression is suggested in which mutations develop in a rapid burst after ablation of replication repair, which implies a threshold compatible with cancer-cell survival.